Project Grant R01HL183379
Award Date 8/1/26
Completion Date 6/30/30
Dollars Obligated $572K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Institute of Environmental Health Sciences awarded Harvard Pilgrim Health Care, Inc. $3.796 million on April 23, 2026, under the Environmental Health program (CFDA 93.113) to examine how early-life exposure to neighborhood environmental disadvantage and nephrotoxicants—including air pollutants and metals—associates with kidney function decline and elevated blood pressure across childhood and early adulthood. The research leverages Project Viva, an ongoing longitudinal pre-birth...
- The National Heart, Lung, and Blood Institute awarded President and Fellows of Harvard College (Harvard T.H. Chan School of Public Health) $1.372 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) for research identifying and validating flavonoid metabolites as biomarkers of plant-rich diets and their associations with cardiovascular risk. The award funds a randomized crossover feeding trial and comprehensive profiling of urinary flavonoid metabolites...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation (doing business as Boston Children's Hospital) $825,533 for Project Grant R01HL182745 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The project investigates glycorna-based control of angiogenesis through heparan sulfate binding growth factors. Research focuses on how vascular endothelial growth factor (VEGF-A) orchestrates vascular and cardiac development by binding...
- The National Institutes of Health National Heart, Lung and Blood Institute awarded Boston Children's Hospital $1,628,604 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct molecular research on atherosclerosis regulation, with performance through June 30, 2028. The project investigates endothelial dysfunction and chronic inflammation as critical regulators of plaque destabilization in atherosclerosis, focusing on the role of CD47 as a cell-surface...
- The National Heart Lung and Blood Institute awarded The Johns Hopkins University $783,962 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate indoor air quality interventions targeting cardiovascular health in patients with chronic obstructive pulmonary disease. The research, titled "Clean Air Heart 2: Targeting Indoor Air Quality to Improve Cardiovascular Health in COPD," addresses the elevated cardiovascular disease mortality risk in COPD...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Brigham & Women's Hospital Inc. $1.789 million on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds integrative computational-experimental approaches to identify rare coding variants that influence lipid metabolism and cardiovascular disease risk. The research combines large-scale population cohort data with high-throughput functional screening using base and prime...
- The National Heart, Lung, and Blood Institute awarded $1.775 million to Boston Children's Hospital on September 1, 2026, to investigate pericyte-to-smooth-muscle-cell transitions in pulmonary arterial hypertension, under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses excessive vascular remodeling in pulmonary arterial hypertension by examining how pericytes—specialized mural cells that maintain capillary stability—transition into smooth muscle-like cells under...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $2,401,048 for Project Grant R01HL184086 on September 1, 2026 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds GO MOMS PREDICT, a prospective study that develops and tests pregnancy-based cardiovascular disease risk assessment models to predict cardiovascular outcomes five years after delivery. The study leverages an existing...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $758,972 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL187185) to investigate overlooked socioeconomic determinants of adolescent cardiovascular health, specifically examining how family wealth, assets, and debts influence cardiovascular risk factors in youth. The research addresses the gap in existing scholarship by focusing on wealth as an economic...
- The National Heart, Lung, and Blood Institute awarded President and Fellows of Harvard College $133,232 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate neural control of cardiovascular physiology via heart-to-brain signaling pathways. The recipient, operating through Harvard Medical School's Office of Research Administration, will conduct research to elucidate how genetically distinct populations of vagal cardiac sensory neurons detect and respond...